Dynamic fluctuations of salivary CGRP levels during migraine attacks: association with clinical variables and phenotypic characterization

Abstract Background Migraine is a complex neurological disorder with significant heterogeneity in its clinical presentation and molecular mechanisms. Calcitonin gene-related peptide (CGRP) has emerged as a key player in migraine pathophysiology, but challenges remain in its utilization as a biomarke...

Full description

Bibliographic Details
Published in:	The Journal of Headache and Pain
Main Authors:	Alicia Alpuente, Victor J. Gallardo, Laila Asskour, Edoardo Caronna, Marta Torres-Ferrus, Patricia Pozo-Rosich
Format:	Article
Language:	English
Published:	BMC 2024-04-01
Subjects:	Migraine Salivary CGRP Biomarker Endophenotyping Personalized medicine
Online Access:	https://doi.org/10.1186/s10194-024-01772-9

Similar Items

Anti-CGRP monoclonal antibodies in chronic migraine with medication overuse: real-life effectiveness and predictors of response at 6 months
by: Edoardo Caronna, et al.
Published: (2021-10-01)

CGRP-targeted medication in chronic migraine - systematic review
by: Renato Oliveira, et al.
Published: (2024-04-01)

Differentially localizing isoforms of the migraine component calcitonin gene-related peptide (CGRP), in the mouse trigeminal ganglion: βCGRP is translated but, unlike αCGRP, not sorted into axons
by: Sofia Lyng Wæver, et al.
Published: (2025-01-01)

Influence of Constipation in the Behavior of Circulating Alpha- and Beta-CGRP Levels in Chronic/High-Frequency Migraine Patients After CGRP Monoclonal Antibodies
by: Gabriel Gárate, et al.
Published: (2025-05-01)

Monoclonal antibodies blocking CGRP for prevention of migraine
by: Alicja Maziarczyk, et al.
Published: (2023-04-01)

Mode and site of action of therapies targeting CGRP signaling
by: Alejandro Labastida-Ramírez, et al.
Published: (2023-09-01)

Interictal burden in migraine patients at the outset of CGRP monoclonal antibody prevention
by: Christian Lampl, et al.
Published: (2024-12-01)

Role of CGRP pathway polymorphisms in migraine: a systematic review and impact on CGRP mAbs migraine therapy
by: Damiana Scuteri, et al.
Published: (2021-07-01)

Blocking CGRP in migraine patients – a review of pros and cons
by: Marie Deen, et al.
Published: (2017-09-01)

CGRP Antagonism and Ketogenic Diet in the Treatment of Migraine
by: Francesca Finelli, et al.
Published: (2024-01-01)

Feasibility of serum CGRP measurement as a biomarker of chronic migraine: a critical reappraisal
by: Mi Ji Lee, et al.
Published: (2018-07-01)

Role of PACAP in migraine: An alternative to CGRP?
by: Song Guo, et al.
Published: (2023-01-01)

PACAP38-induced migraine attacks are independent of CGRP signaling: a randomized controlled trial
by: Mohammad Al-Mahdi Al-Karagholi, et al.
Published: (2025-04-01)

CGRP: New Focus in Migraine
by: Necdet Karlı, et al.
Published: (2022-03-01)

Shared and independent roles of CGRP and PACAP in migraine pathophysiology
by: Adisa Kuburas, et al.
Published: (2023-04-01)

Change of CGRP Plasma Concentrations in Migraine after Discontinuation of CGRP-(Receptor) Monoclonal Antibodies
by: Bianca Raffaelli, et al.
Published: (2023-01-01)

The Vasodilatory Response to CGRP of the Anterior and Posterior Cerebral Circulation in Migraine
by: Darja Visočnik, et al.
Published: (2022-05-01)

Unmasking the relationship between CGRP and glutamate: from peripheral excitation to central sensitization in migraine
by: Fahimeh Martami, et al.
Published: (2025-05-01)

Anti-CGRP monoclonal antibodies in the treatment of migraine in women: impact on menstrual relared migraine and algodysmenorrhea
by: Anna V. Berdnikova, et al.
Published: (2023-10-01)

Onabotulinumtoxin-A: Previous Prophylactic Treatment Might Improve Subsequent Anti-CGRP Monoclonal Antibodies Response in Patients with Chronic Migraine
by: Giulia Ceccardi, et al.
Published: (2023-11-01)

CGRP en migraña: de la fisiopatología a la terapéutica
by: S. Santos-Lasaosa, et al.
Published: (2022-06-01)

Average steps per day as marker of treatment response with anti-CGRP mAbs in adults with chronic migraine: a pilot study
by: Frederik Thal Jantzen, et al.
Published: (2024-08-01)

Health Technology Assessment: Evaluation of 8 CGRP-Targeted Therapy Drugs for the Treatment of Migraine
by: Li M, et al.
Published: (2025-02-01)

Effect of soy isoflavones supplementation on migraine characteristics, mental status and calcitonin gene-related peptide (CGRP) levels in women with migraine: results of randomised controlled trial
by: Maedeh Babapour, et al.
Published: (2022-07-01)

In search of a gold standard patient-reported outcome measure to use in the evaluation and treatment-decision making in migraine prevention. A real-world evidence study
by: Alicia Alpuente, et al.
Published: (2021-12-01)

Sustained response to atogepant in episodic migraine: post hoc analyses of a 12-week randomized trial and a 52-week long-term safety trial
by: Richard B. Lipton, et al.
Published: (2024-05-01)

A study of differential microRNA expression profile in migraine: the microMIG exploratory study
by: V. J. Gallardo, et al.
Published: (2023-02-01)

Safety of anti-CGRP monoclonal antibodies in patients with migraine during the COVID-19 pandemic: Present and future implications
by: E. Caronna, et al.
Published: (2021-10-01)

Effectiveness and Safety of CGRP-Targeted Therapies Combined with Lifestyle Modifications for Chronic Migraine in Korean Pediatric Patients: A Retrospective Study
by: Ji-Hoon Na, et al.
Published: (2025-05-01)

CGRP-induced migraine-like headache in persistent post-traumatic headache attributed to mild traumatic brain injury
by: Håkan Ashina, et al.
Published: (2022-10-01)

Disrupting Migraine Dynamics: A Narrative Review of the Consequences of Modern Anti-CGRP Monoclonal Antibody Therapies
by: Dawn C. Buse, et al.
Published: (2025-05-01)

Rapid resolution of migraine symptoms after initiating the preventive treatment eptinezumab during a migraine attack: results from the randomized RELIEF trial
by: Jessica Ailani, et al.
Published: (2022-06-01)

Safety considerations in the treatment with anti-CGRP(R) monoclonal antibodies in patients with migraine
by: Britt W. H. Van Der Arend, et al.
Published: (2024-04-01)

“Triaging” Chronic Migraine Patients in Need of CGRP(r) Monoclonal Antibodies
by: Paolo Martelletti
Published: (2020-04-01)

Patients’ Experiences During the Long Journey Before Initiating Migraine Prevention with a Calcitonin Gene-Related Peptide (CGRP) Monoclonal Antibody (mAb)
by: Elizabeth Seng, et al.
Published: (2024-09-01)

Effectiveness and Safety of OnabotulinumtoxinA in Adolescent Patients with Chronic Migraine
by: Laura Gómez-Dabó, et al.
Published: (2024-05-01)

Serum CGRP Changes following Ultrasound-Guided Bilateral Greater-Occipital-Nerve Block
by: Abdelrahman Abbas, et al.
Published: (2022-02-01)

Untangling the mess of CGRP levels as a migraine biomarker: an in-depth literature review and analysis of our experimental experience
by: Gabriel Gárate, et al.
Published: (2024-04-01)

A proof-of-concept study on CGRP plasma levels of migraineurs during a 6-month treatment with ERENUMAB
by: Giuseppe Tringali, et al.
Published: (2020-10-01)

Calcitonin gene relating peptide inhibitors in combination for migraine treatment: A mini-review
by: Tulsi Shah, et al.
Published: (2023-03-01)